Overview - The CRO industry in China has developed rapidly in recent years, particularly due to clear national pharmaceutical policies, accelerated medical reforms, and the expansion of the medical insurance market [1][9] - By 2024, the CRO market in China is expected to reach 89.22 billion yuan, with a year-on-year growth of 5.19%, and the clinical CRO market is projected to reach 46.31 billion yuan, growing by 4.68% [1][9] Industry Development - The CRO industry in China began in 1996 with the establishment of the first CRO company by MDS Pharmaceutical Services [5] - The industry has undergone significant changes, including a major reshuffle in 2015 due to quality concerns, leading to the elimination of many low-level CROs [5][10] - Major players like WuXi AppTec and Tigermed have gained competitive advantages through capital strength and project experience [5][10] Market Policies - The Chinese government has issued various policies to support the pharmaceutical manufacturing industry, encouraging new drug research and optimizing approval processes [6][7] Industry Chain - The CRO industry chain includes upstream components like experimental animals and biological reagents, midstream CRO companies, and downstream clients such as pharmaceutical companies and research institutions [8] - The pharmaceutical industry is the primary client for CROs, outsourcing clinical research to reduce costs and improve efficiency [8] Current Market Status - The global CRO market is projected to reach 90.03 billion USD in 2024, with a year-on-year growth of 9.65%, and the clinical CRO market is expected to reach 62.57 billion USD, growing by 8.35% [9] - The demand for high-quality medical resources is increasing, particularly in areas like rare diseases and public health events, driving the growth of the CRO market [9] Competitive Landscape - The CRO market in China is becoming increasingly competitive, with a notable shift towards Asia due to cost advantages and a large patient population [10] - Leading companies such as Tigermed and Kanglongda are recognized for their comprehensive clinical research services and have significant market shares [10][12] Future Trends - The quality management standards for drug development are expected to improve, leading to increased concentration in the industry as smaller CROs face challenges [13][14] - There will be a rise in specialized CROs focusing on specific disease areas, providing differentiated services to pharmaceutical companies [13][14]

Core Viewpoint - Goldman Sachs upgraded Tiger Med's stock rating from Neutral to Buy [1] Group 1 - The upgrade reflects a positive outlook on Tiger Med's future performance [1]

Core Viewpoint - Goldman Sachs has upgraded the rating of Tiger Medical's A-shares to "Buy" with a target price of 77.10 RMB [1] Group 1 - The upgrade reflects a positive outlook on Tiger Medical's performance and potential growth in the market [1]

Summary of Conference Call Records Industry Overview - The A-share pharmaceutical sector underperformed the market in September 2025, declining by 1.7%, while the Hong Kong Hang Seng Healthcare Index rose by 5.2%, lagging behind the Hang Seng Index's 7.1% increase. The S&P 500 healthcare index increased by 1.6%, lower than the S&P 500's 3.5% rise [1][3][4]. Key Companies and Insights Changchun High-tech - Significant investment in R&D, focusing on pediatrics, oncology, and women's health. New products such as Meishiya and Jinbeixing are expected to ramp up quickly. Early-stage products like 047 and PD-1 agonist 120 have differentiated advantages, indicating substantial long-term growth potential [1][5]. Enhua Pharmaceutical - As a leader in the precision medicine sector, Enhua's main business is immune to centralized procurement risks. New product 60,001 is expected to mitigate risks associated with the procurement of etomidate. The company has a multi-pipeline layout in the CNS field, with a low current valuation [1][6]. Lepu Medical - Traditional business has stabilized, with strategic focus on innovative cardiovascular and metabolic drugs. Products like Mingweisheng's 109 injection and 105 injection are in clinical trials for obesity-related conditions. The company is also expanding into non-reimbursed areas [1][7]. Terbium Biologics - Recent approval for Pegbivac's use in chronic hepatitis B patients marks a significant clinical milestone. The growth hormone Tigebin is expected to drive performance in 2026 [1][8]. CRO Sector - Despite short-term impacts from safety legislation, the CRO industry is expected to recover. Companies like WuXi AppTec and Tigermed are recommended due to their strong market positions [2][9][22]. Market Trends and Predictions - The overall performance of the pharmaceutical sector in October 2025 is expected to be volatile, influenced by U.S.-China relations and tariff wars. However, the innovative drug supply chain remains promising. New recommendations include Changchun High-tech, Enhua Pharmaceutical, and Lepu Medical, while maintaining recommendations for Hengrui Medicine and Kelun Pharmaceutical [2][10]. Long-term Industry Outlook - The structural trends in the innovative drug industry and the advantages of China's engineering talent remain intact despite macro uncertainties. The external licensing model is considered safe under geopolitical conditions, with clear property rights [3][12]. Notable Companies to Watch - In October, companies such as Hengrui, Kangfang, and Rongchang Biologics are highlighted for their potential catalysts due to core asset data disclosures [2][13]. Additional Insights - The CRO sector is expected to see valuation recovery, with companies like WuXi AppTec projected to achieve double-digit revenue growth in Q3 2025 [22]. - JD Health is noted for its strong growth potential in the consumer healthcare sector, with revenue growth expected to exceed 20% in 2025 [23]. This summary encapsulates the key points from the conference call records, focusing on the pharmaceutical industry and specific companies within it.

Core Viewpoint - The Hong Kong pharmaceutical stocks continue to decline, particularly in the CRO sector, with significant drops in share prices for several companies [1] Group 1: Company Performance - Junshi Biosciences (01877.HK) decreased by 7.98%, trading at 27.22 HKD [1] - Kanglong Chemical (03759.HK) fell by 6.3%, with a price of 24.4 HKD [1] - Kelun Pharmaceutical (06821.HK) saw a decline of 5.69%, priced at 91.95 HKD [1] - Tigermed (03347.HK) dropped by 3.48%, trading at 42.4 HKD [1]

Group 1 - Pharmaceutical stocks continue to decline, with CRO sector leading the drop, including significant declines in Junshi Biosciences (down 7.98%), Kanglong Chemical (down 6.3%), Kelaiying (down 5.69%), and Tigermed (down 3.48%) [1] - Recent market trends in the pharmaceutical sector are attributed to several factors, including a deal between the Trump administration and Pfizer to lower drug prices in the U.S., which is seen as a reconciliation signal between U.S. pharmaceutical companies and the government [1] - The U.S. Senate's consideration of a bill to prohibit certain Chinese biotech companies from receiving federal funding has led to a significant pullback in the CXO sector [1] Group 2 - Recent tensions in U.S.-China trade relations have escalated, with a renewed tariff war expected; however, the pharmaceutical market is not overly concerned as the industry has shown resilience since the first tariff war in April [2] - The innovative drug and CXO sectors have outperformed other sub-industries, driven by China's rising independent innovation and ongoing overseas business development, which are less affected by tariffs [2] - The CXO sector benefits from strong upstream and downstream relationships and a service pricing model that allows companies to pass on tariff pressures relatively freely [2]

Group 1 - Pharmaceutical stocks continued to decline, with CRO sector leading the drop, including significant declines in companies like Junshi Biosciences (-7.98%), Kanglong Chemical (-6.3%), and others [1] - Recent market trends in the pharmaceutical sector are attributed to several factors, including a deal between the Trump administration and Pfizer to lower drug prices in the U.S., which is seen as a reconciliation signal between U.S. pharmaceutical companies and the government [1] - The U.S. Senate's consideration of a bill to prohibit certain Chinese biotech companies from receiving federal funding has led to a significant pullback in the CXO sector [1] Group 2 - Tensions in U.S.-China trade relations have escalated, with renewed tariff battles expected; however, the pharmaceutical market is not overly concerned as the industry has shown resilience [2] - The innovative drug and CXO sectors have performed exceptionally well since the first tariff battle in April, driven by China's rising independent innovation and ongoing overseas business development [2] - The CXO sector's strong business model allows companies to transfer tariff pressures relatively freely due to strong upstream and downstream relationships [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED COUNSULTING CO., LTD. 本公司董事（「董 事」）會（「董事會」）謹 此 宣 佈，於2025年10月10日，本 公 司、 本 公 司 全 資 子 公 司 嘉 興 欣 格 醫 藥 科 技 有 限 公 司（與 本 公 司 合 稱「賣 方」）與 方 達 醫 藥 技 術（上 海）有 限 公 司（「買 方」）（方 達 控 股 公 司（「方達控股」連 同 其 子 公 司 統 稱「方達集團」）的 全 資 子 公 司）簽 訂 股 份 轉 讓 協 議（「股份轉讓協 議」），據 此，買 方 有 條 件 同 意 收 購，而 賣 方 有 條 件 同 意 出 售 上 海 觀 合 醫 藥 科 技 股 份 有 限 公 司（「目標公司」）的 全 部 已 發 行 股 本，總 代 價 為 人 民 幣 270,000,0 ...

Group 1 - The core point of the article is that Tiger Med (03347) has signed a share transfer agreement to sell all issued shares of Shanghai Guanhao Medical Technology Co., Ltd. to Fangda Pharmaceutical Technology (Shanghai) Co., Ltd. for a total consideration of RMB 270 million [1] - The transaction is expected to enhance the operational efficiency of the group by optimizing resource allocation and integrating internal resources [2] - The target group, which primarily engages in clinical trial services, will remain a subsidiary of the company after the sale, allowing for better coordination of business functions within the overall group structure [1][2] Group 2 - The sale is anticipated to promote synergies within the group by simplifying decision-making processes and achieving centralized management [2] - Tiger Med is recognized as a leading provider of comprehensive biopharmaceutical research and development services in China, with a growing global influence [1] - Fangda Group, the buyer, provides research, analysis, and development services throughout the entire product discovery and development process [1]

公告称，出售事项使集团可透过整合内部资源，优化其资源配置并提升营运效率。由于方达集团亦为集 团子公司，出售事项有助于在集团整体架构内更好地协调业务职能及促进协同效应。透过将目标集团业 务整合至方达集团旗下，集团可实现集中管理并简化决策制定程序，从而提升成本效益与营运专注度。 截至本公告日期，方达控股为公司的子公司，其股份于香港联合交易所有限公司上市(股份代号： 3347)。因此，在完成出售事项后，目标公司以及观合医药(香港)有限公司和无锡观合医学检验所有限公 司(均为目标公司的子公司，连同目标公司统称为"目标集团")将仍作为公司的子公司。 公司是中国领先的综合生物制药研发服务提供商，且全球影响力正在不断扩大，主要从事为国内外创新 药和医疗器械企业提供创新药、医疗器械和生物技术相关产品的一站式专业临床研究服务。目标集团主 要从事临床试验服务。方达集团从事提供贯穿整个产品发现及开发过程中的研究、分析及开发服务。 智通财经APP讯，泰格医药(03347)发布公告，于2025年10月10日，公司、公司全资子公司嘉兴欣格医药 科技有限公司(与公司合称"卖方")与方达医药技术(上海)有限公司("买方")(方达控股公司(" ...